获取途径

作者

A. Liu X. Yin J. Wen J. Peng K. Zhao Z. Huang H. Feng X. Meng

作者单位

⁴Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China ⁶Department of radiation oncology, The Affiliated Hospital of Qingdao University, Qingdao, China ³Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Department of Radiation Oncology, Jinan, Shandong, China ¹School of Clinical Medicine, Shandong Second Medical University, Weifang, China ⁷Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China ⁵Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China ²Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

刊名

International Journal of Radiation Oncology*Biology*Physics

年份

2025

卷号

Vol.123 No.1Suppl

页码

e184

ISSN

0360-3016

摘要

Purpose/Objective Primary pulmonary sarcoma is a rare malignant tumor that lacks specific treatment options. In particular, for the evaluation of the efficacy of radiation therapy , data on the effectiveness of RT are limited. This study aims to evaluate the efficacy of radiotherapy in the treatment of pulmonary sarcoma. Materials/Methods We retrospectively analyzed 47 non-surgical primary pulmonary sarcoma patients from three Chinese tertiary centers , stratified into RT and non-RT groups. I...更多

Purpose/Objective Primary pulmonary sarcoma is a rare malignant tumor that lacks specific treatment options. In particular, for the evaluation of the efficacy of radiation therapy , data on the effectiveness of RT are limited. This study aims to evaluate the efficacy of radiotherapy in the treatment of pulmonary sarcoma. Materials/Methods We retrospectively analyzed 47 non-surgical primary pulmonary sarcoma patients from three Chinese tertiary centers , stratified into RT and non-RT groups. In the RT group, 15 patients received definitive RT , while 11 received palliative RT. Systemic therapies included anthracycline-ifosfamide chemotherapy and chemotherapy combined with immunotherapy/targeted agents. Tumor response was assessed per RECIST 1.1, with local control defined as non-progression of irradiated lesions. Kaplan-Meier method was used for survival analysis Results The RT group demonstrated a significantly prolonged median progression-free survival compared to the non-RT group . The ORR was 38.5% in the RT group, including 1 complete response . In contrast, the non-RT group achieved an ORR of 28.6%, with no CR observed . Among 31 irradiated lesions with evaluable local control data, the local control rate was 88%. Additionally, patients in the RT group who received Anlotinib showed a better survival trend, with a median PFS of 12.1 months. Conclusion Radiotherapy significantly improves PFS and provides robust local tumor control in unresectable PPS, supporting its integration into multimodal management. Notably, 1 patient achieved CR after definitive RT, demonstrating the potential for durable remission in selected cases. While ORR differences were non-significant, the survival benefit and observed CR underscore RT’s role in delaying disease progression and inducing deep responses. Further studies are warranted to optimize RT dose-fractionation and validate synergies with targeted therapies like anlotinib.收起

文献类型

期刊

浏览量

2